PubMed=12579306; DOI=10.3892/ijo.22.3.535
Nishio J., Iwasaki H., Ishiguro M., Ohjimi Y., Fujita C., Ikegami H., Ariyoshi A., Naito M., Kaneko Y., Kikuchi M.
Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization.
Int. J. Oncol. 22:535-542(2003)

PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)

PubMed=22911243; DOI=10.1155/2012/148614; PMCID=PMC3403520
Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S., Munthe E., Myklebost O.
Characterization of liposarcoma cell lines for preclinical and biological studies.
Sarcoma 2012:148614.1-148614.9(2012)

PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014)

PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015)